Q3 FY26: revenue up 16.5% YoY, PAT down 45% on exceptional items

Exceptional ItemResults View source PDF Explain this filing

JUBLPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-3.3%Reaction day

₹964.80

prior close

₹950.55

announcement price

In-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)-0.3%-3.0% vs market

Pharmaceuticals peers, median of 159sector-0.6%-2.7% vs sector

On the reaction day the stock moved 3.0 pts less than Nifty Smallcap 250 and 2.7 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.5

10m

-0.2

15m

+0.7

30m

+1.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-3.3-0.3-3.0-0.6-2.7

Next day

-2.5+2.2-4.7+1.2-3.7

-3.1+2.7-5.8+1.8-4.8

-2.8+2.8-5.7+1.3-4.2

-1.5+2.1-3.6+0.7-2.2

-5.6+0.4-6.1+0.0-5.7

-6.2+1.1-7.4-0.2-6.1

15d

-10.3-0.2-10.1-2.3-8.0

-14.6-3.1-11.5-4.4-10.2

-11.6-6.5-5.1-7.2-4.3

-0.8+8.3-9.1+2.7-3.5

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 159Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Consolidated Q3 FY26 revenue rose 16.5% YoY to Rs 21,225 million. Net profit fell 45% to Rs 558 million hit by exceptional expenses of Rs 397 million, mainly Rs 443 million for OAI remediation at Montreal Canada facility. For 9M FY26, revenue grew 12.9% to Rs 59,896 million but PAT dropped 59% to Rs 2,782 million. Standalone figures distorted by slump sale of API business to wholly-owned subsidiary Jubilant Biosys completed Sept 2025, now classified as discontinued ops. Radiopharma segment grew 11% to Rs 27,001 million for 9M.

Likely market impact

Mixed. Revenue growth healthy but sharp PAT fall on one-off exceptional costs. Watch Montreal remediation progress.